-
公开(公告)号：US08889732B2
公开(公告)日：2014-11-18
申请号：US13503560
申请日：2010-10-22
IPC分类号： A61K31/38 , C07D333/32 , C07D231/18 , C07D333/38 , C07D401/12 , C07D409/12 , C07D409/14 , C07D409/04 , C07D333/40
CPC分类号： C07D409/14 , C07D231/18 , C07D333/32 , C07D333/38 , C07D333/40 , C07D401/12 , C07D409/04 , C07D409/12
摘要： Fused heterocyclic compounds useful for prevention, treatment or improvement of diseases against which activation of the thrombopoietin receptor is effective are provided.A compound represented by the formula (I) (wherein R1 is an aryl group fused to a saturated ring or the like, A, B, L1, R2, L2, L3, Y, L4, R3 and X are defined in the description), a tautomer, prodrug or a pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 提供了可用于预防，治疗或改善血小板生成素受体活化有效的疾病的融合杂环化合物。 式（I）表示的化合物（其中R 1是与饱和环等稠合的芳基A，B，L1，R2，L2，L3，Y，L4，R3和X在说明书中定义） ，该化合物或其溶剂化物的互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US20120209005A1
公开(公告)日：2012-08-16
申请号：US13503560
申请日：2010-10-22
IPC分类号： C07D409/14 , C07D333/32 , C07D401/12 , C07D409/12 , C07D231/18
CPC分类号： C07D409/14 , C07D231/18 , C07D333/32 , C07D333/38 , C07D333/40 , C07D401/12 , C07D409/04 , C07D409/12
摘要： Fused heterocyclic compounds useful for prevention, treatment or improvement of diseases against which activation of the thrombopoietin receptor is effective are provided.A compound represented by the formula (I) (wherein R1 is an aryl group fused to a saturated ring or the like, A, B, L1, R2, L2, L3, Y, L4, R3 and X are defined in the description), a tautomer, prodrug or a pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 提供了可用于预防，治疗或改善血小板生成素受体活化有效的疾病的融合杂环化合物。 式（I）表示的化合物（其中R 1是与饱和环等稠合的芳基A，B，L1，R2，L2，L3，Y，L4，R3和X在说明书中定义） ，该化合物或其溶剂化物的互变异构体，前药或药学上可接受的盐。
-
3.发明申请公开(公告)号：US20090198060A1
公开(公告)日：2009-08-06
申请号：US12303436
申请日：2007-06-07
申请人： Katsuaki Miyaji , Shunsuke Iwamoto , Yukihiro Shigeta , Yutaka Hirokawa , Shingo Oowada , Takanori Nakamura , Norihisa Ishiwata
发明人： Katsuaki Miyaji , Shunsuke Iwamoto , Yukihiro Shigeta , Yutaka Hirokawa , Shingo Oowada , Takanori Nakamura , Norihisa Ishiwata
IPC分类号： C07D403/12 , C07D401/12
CPC分类号： C07D231/22 , C07D401/12 , C07D403/12
摘要： Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided.A compound represented by the formula (I) (wherein R1, R2, R3, L1, L2, L3, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 提供了有效预防，治疗或改善血小板生成素受体激活有效的疾病的化合物。 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3，L1，L2，L3，X和Y在说明书中定义），互变异构体，前药或药学上可接受的盐。
-
4.发明授权Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators 有权含氮杂环化合物和血小板生成素受体激活剂公开(公告)号：US08093251B2
公开(公告)日：2012-01-10
申请号：US12303436
申请日：2007-06-07
申请人： Katsuaki Miyaji , Shunsuke Iwamoto , Yukihiro Shigeta , Yutaka Hirokawa , Shingo Oowada , Takanori Nakamura , Norihisa Ishiwata
发明人： Katsuaki Miyaji , Shunsuke Iwamoto , Yukihiro Shigeta , Yutaka Hirokawa , Shingo Oowada , Takanori Nakamura , Norihisa Ishiwata
IPC分类号： C07D401/12 , C07D403/12 , A61K31/454 , A61K31/496 , A61P7/00
CPC分类号： C07D231/22 , C07D401/12 , C07D403/12
摘要： Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided.A compound represented by the formula (I) (wherein R1, R2, R3, L1, L2, L3, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 提供了有效预防，治疗或改善血小板生成素受体激活有效的疾病的化合物。 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3，L1，L2，L3，X和Y在说明书中定义），互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US08134013B2
公开(公告)日：2012-03-13
申请号：US11721786
申请日：2005-12-14
申请人： Katsuaki Myaji , Shunsuke Iwamoto , Satoshi Nakano , Hirofumi Ota , Yukihiro Shigeta , Yutaka Hirokawa , Kazufumi Yanagihara , Koji Toyama , Shingo Owada , Masato Horikawa , Norihisa Ishiwata
发明人： Katsuaki Myaji , Shunsuke Iwamoto , Satoshi Nakano , Hirofumi Ota , Yukihiro Shigeta , Yutaka Hirokawa , Kazufumi Yanagihara , Koji Toyama , Shingo Owada , Masato Horikawa , Norihisa Ishiwata
IPC分类号： C07D409/02 , A61K31/40
CPC分类号： C07D231/18
摘要： The present invention provides compounds useful for prevention, treatment or alleviation of diseases against which activation of the thrombopoietin receptor is effective.A compound represented by the formula (1): wherein A, B, R1, L1, R2, L2, L3, Y, L4, R3 and X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 本发明提供了可用于预防，治疗或缓解血小板生成素受体活化有效的疾病的化合物。 由式（1）表示的化合物：其中A，B，R1，L1，R2，L2，L3，Y，L4，R3和X与说明书中定义的相同，互变异构体，前药或药学上可接受的盐 化合物或其溶剂合物。
-
公开(公告)号：US07968542B2
公开(公告)日：2011-06-28
申请号：US11994502
申请日：2006-07-13
申请人： Katsuaki Miyaji , Kazufumi Yanagihara , Yukihiro Shigeta , Shunsuke Iwamoto , Masato Horikawa , Yutaka Hirokawa , Shingo Owada , Satoshi Nakano , Hirofumi Ota , Norihisa Ishiwata
发明人： Katsuaki Miyaji , Kazufumi Yanagihara , Yukihiro Shigeta , Shunsuke Iwamoto , Masato Horikawa , Yutaka Hirokawa , Shingo Owada , Satoshi Nakano , Hirofumi Ota , Norihisa Ishiwata
IPC分类号： C07D401/14 , C07D409/14 , C07D413/14 , A61K31/381 , A61P7/00
CPC分类号： C07D409/14 , C07D333/32 , C07D333/38 , C07D413/14
摘要： A compound represented by the formula (I) (wherein R1, R2, R3 and R4 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3和R4如说明书中所定义），互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US20110092496A1
公开(公告)日：2011-04-21
申请号：US12955477
申请日：2010-11-29
申请人： Katsuaki MIYAJI , Kazufumi Yanagihara , Yukihiro Shigeta , Shunsuke Iwamoto , Masato Horikawa , Yutaka Hirokawa , Shingo Owada , Satoshi Nakano , Hirofumi Ota , Norihisa Ishiwata
发明人： Katsuaki MIYAJI , Kazufumi Yanagihara , Yukihiro Shigeta , Shunsuke Iwamoto , Masato Horikawa , Yutaka Hirokawa , Shingo Owada , Satoshi Nakano , Hirofumi Ota , Norihisa Ishiwata
IPC分类号： A61K31/5377 , C07D405/12 , C07D409/12 , C07D233/96 , C07D231/10 , C07D333/22 , C07D261/08 , C07D411/12 , A61K31/497 , A61K31/4436 , A61K31/4178 , A61K31/4155 , A61K31/422 , A61K31/4025 , A61K31/381 , A61P7/00
CPC分类号： C07D409/14 , C07D333/32 , C07D333/38 , C07D413/14
摘要： A compound represented by the formula (I) (wherein R1, R2, R3 and R4 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3和R4如说明书中所定义），互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US20090131659A1
公开(公告)日：2009-05-21
申请号：US11721786
申请日：2005-12-14
申请人： Katsuaki Miyaji , Shunsuke Iwamoto , Satoshi Nakano , Hirofumi Ota , Yukihiro Shigeta , Yutaka Hirokawa , Kazufumi Yanagihara , Koji Toyama , Shingo Owada , Masato Horikawa , Norihisa Ishiwata
发明人： Katsuaki Miyaji , Shunsuke Iwamoto , Satoshi Nakano , Hirofumi Ota , Yukihiro Shigeta , Yutaka Hirokawa , Kazufumi Yanagihara , Koji Toyama , Shingo Owada , Masato Horikawa , Norihisa Ishiwata
IPC分类号： C07D413/12 , C07D409/14
CPC分类号： C07D231/18
摘要： The present invention provides compounds useful for prevention, treatment or alleviation of diseases against which activation of the thrombopoietin receptor is effective.A compound represented by the formula (1): wherein A, B, R1, L1, R2, L2, L3, Y, L4, R3 and X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 本发明提供了可用于预防，治疗或缓解血小板生成素受体活化有效的疾病的化合物。 由式（1）表示的化合物：其中A，B，R1，L1，R2，L2，L3，Y，L4，R3和X与说明书中定义的相同，互变异构体，前药或药学上可接受的盐 化合物或其溶剂合物。
-
公开(公告)号：US20090118500A1
公开(公告)日：2009-05-07
申请号：US11994502
申请日：2006-07-13
申请人： Katsuaki Miyaji , Kazufumi Yanagihara , Yukihiro Shigeta , Shunsuke Iwamoto , Masato Horikawa , Yutaka Hirokawa , Shingo Owada , Satoshi Nakano , Hirofumi Ota , Norihisa Ishiwata
发明人： Katsuaki Miyaji , Kazufumi Yanagihara , Yukihiro Shigeta , Shunsuke Iwamoto , Masato Horikawa , Yutaka Hirokawa , Shingo Owada , Satoshi Nakano , Hirofumi Ota , Norihisa Ishiwata
IPC分类号： C07D495/04 , C07D409/12 , C07D409/02
CPC分类号： C07D409/14 , C07D333/32 , C07D333/38 , C07D413/14
摘要： A compound represented by the formula (I) (wherein R1, R2, R3 and R4 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3和R4如说明书中所定义），互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US07576115B2
公开(公告)日：2009-08-18
申请号：US11837659
申请日：2007-08-13
申请人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
发明人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
IPC分类号： A61K31/415 , C07D231/10
CPC分类号： C07D417/12 , C07D231/18 , C07D295/192 , C07D333/32 , C07D333/38 , C07D403/12 , C07D409/12
摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or is pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当A是氮原子时，B不是NH），R1是C2 -14芳基，L1是键，CR10R11，氧原子，硫原子或NR12，X是OR13，SR13或NR14NR15，R2是氢原子，甲酰基，C1-10烷基等， L2是键或类似物，L3是键，CR17R18，氧原子，硫原子或NR19，L4是键，CR20R21，氧原子，硫原子或NR22，Y是氧原子，硫原子 原子或NR 23，并且R 3是C 12-14芳基，互变异构体，前药或化合物或其溶剂合物的药学上可接受的盐。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.031 秒)
